SOLIRIS® is indicated to treat:

  • Paroxysmal Nocturnal Hemoglobinuria
  • Atypical Hemolytic Uremic Syndrome
  • Generalized Myasthenia Gravis
  • Neuromyelitis Optica Spectrum Disorder

Drug Summary

SOLIRIS, Eculizumab, is a monoclonal antibody in the category of immunosuppressive drugs used for the treatment of hemolytic blood disorders. SOLIRIS works by selectively slowing down the complement system in the human body. Recommended administraiton of SOLIRIS is an intravenous infusion weekly for 4 weeks following by the 5th dose 1 week later and then every 2 weeks thereafter.

More Information

For more information, click here to visit the manufacturer’s website:

Ready to Start with Specialty Infusion?

It’s easy to transition your treatment to Specialty Infusion. Here’s how it works:

Ask your doctor to send a prescription, clinical notes, demographics and your insurance card.

One of our Care Coordinators will contact you to confirm receipt of your referral and provide guidance on the next steps.

Your Care Coordinator will contact your insurance company to conduct an investigation of benefits and initiate authorization to ensure coverage of your treatment.

Our team works diligently to expedite the authorization process. Once approval is obtained, your Care Coordinator will contact you to schedule an appointment.